{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:28:53Z","timestamp":1780511333801,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":22,"publisher":"Springer New York","isbn-type":[{"value":"9781493973507","type":"print"},{"value":"9781493973521","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7352-1_13","type":"book-chapter","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T11:24:54Z","timestamp":1508153094000},"page":"149-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Analysis of Complement Activation by Nanoparticles"],"prefix":"10.1007","author":[{"given":"Barry W.","family":"Neun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna N.","family":"Ilinskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina A.","family":"Dobrovolskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"issue":"12","key":"13_CR1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.imbio.2016.07.004","volume":"221","author":"DG Calame","year":"2016","unstructured":"Calame DG, Mueller-Ortiz SL, Wetsel RA (2016) Innate and adaptive immunologic functions of complement in the host response to Listeria monocytogenes infection. Immunobiology 221(12):1407\u20131417. doi:\n                    10.1016\/j.imbio.2016.07.004","journal-title":"Immunobiology"},{"issue":"21","key":"13_CR2","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1111\/bph.13268","volume":"172","author":"J Szebeni","year":"2015","unstructured":"Szebeni J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, Rampton D, Weiss G, Folkersen J (2015) Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol 172(21):5025\u20135036. doi:\n                    10.1111\/bph.13268","journal-title":"Br J Pharmacol"},{"issue":"3","key":"13_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.bbrc.2015.06.177","volume":"468","author":"J Szebeni","year":"2015","unstructured":"Szebeni J, Storm G (2015) Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. Biochem Biophys Res Commun 468(3):490\u2013497. doi:\n                    10.1016\/j.bbrc.2015.06.177","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"13_CR4","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, Szebeni J, Weiss G (2014) Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 99(11):1671\u20131676. doi:\n                    10.3324\/haematol.2014.111492","journal-title":"Haematologica"},{"issue":"2","key":"13_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","volume":"61","author":"J Szebeni","year":"2014","unstructured":"Szebeni J (2014) Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 61(2):163\u2013173. doi:\n                    10.1016\/j.molimm.2014.06.038","journal-title":"Mol Immunol"},{"issue":"10","key":"13_CR6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/nbt1332","volume":"25","author":"ST Reddy","year":"2007","unstructured":"Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O'Neil CP, Lee LK, Swartz MA, Hubbell JA (2007) Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 25(10):1159\u20131164. doi:\n                    10.1038\/nbt1332","journal-title":"Nat Biotechnol"},{"issue":"1","key":"13_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.intimp.2013.05.012","volume":"17","author":"SM Moghimi","year":"2013","unstructured":"Moghimi SM, Wibroe PP, Szebeni J, Hunter AC (2013) Surfactant-mediated complement activation in beagle dogs. Int Immunopharmacol 17(1):33\u201334. doi:\n                    10.1016\/j.intimp.2013.05.012","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"13_CR8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","volume":"63","author":"J Szebeni","year":"2011","unstructured":"Szebeni J, Muggia F, Gabizon A, Barenholz Y (2011) Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 63(12):1020\u20131030. doi:\n                    10.1016\/j.addr.2011.06.017","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"13_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1089\/nat.2015.0584","volume":"26","author":"L Shen","year":"2016","unstructured":"Shen L, Engelhardt JA, Hung G, Yee J, Kikkawa R, Matson J, Tayefeh B, Machemer T, Giclas PC, Henry SP (2016) Effects of repeated complement activation associated with chronic treatment of Cynomolgus monkeys with 2\u2032-O-Methoxyethyl modified antisense oligonucleotide. Nucleic Acid Ther 26(4):236\u2013249. doi:\n                    10.1089\/nat.2015.0584","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"13_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1124\/jpet.114.219378","volume":"351","author":"L Shen","year":"2014","unstructured":"Shen L, Frazer-Abel A, Reynolds PR, Giclas PC, Chappell A, Pangburn MK, Younis H, Henry SP (2014) Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans. J Pharmacol Exp Ther 351(3):709\u2013717. doi:\n                    10.1124\/jpet.114.219378","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"13_CR11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S1567-5769(02)00142-X","volume":"2","author":"SP Henry","year":"2002","unstructured":"Henry SP, Beattie G, Yeh G, Chappel A, Giclas P, Mortari A, Jagels MA, Kornbrust DJ, Levin AA (2002) Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2(12):1657\u20131666","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"13_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","volume":"14","author":"A Chanan-Khan","year":"2003","unstructured":"Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, Muggia FM (2003) Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil\u00ae): possible role in hypersensitivity reactions. Ann Oncol 14(9):1430\u20131437","journal-title":"Ann Oncol"},{"issue":"3","key":"13_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/jbm.a.30711","volume":"78","author":"A Vonarbourg","year":"2006","unstructured":"Vonarbourg A, Passirani C, Saulnier P, Simard P, Leroux JC, Benoit JP (2006) Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A 78(3):620\u2013628. doi:\n                    10.1002\/jbm.a.30711","journal-title":"J Biomed Mater Res A"},{"issue":"2","key":"13_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1021\/bc0603539","volume":"18","author":"DW Bartlett","year":"2007","unstructured":"Bartlett DW, Davis ME (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 18(2):456\u2013468. doi:\n                    10.1021\/bc0603539","journal-title":"Bioconjug Chem"},{"issue":"1\u20132","key":"13_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijpharm.2007.04.036","volume":"342","author":"S Nagayama","year":"2007","unstructured":"Nagayama S, Ogawara K, Fukuoka Y, Higaki K, Kimura T (2007) Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm 342(1\u20132):215\u2013221. doi:\n                    10.1016\/j.ijpharm.2007.04.036","journal-title":"Int J Pharm"},{"issue":"9\u201310","key":"13_CR16","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1166\/jnn.2006.406","volume":"6","author":"O Al-Hanbali","year":"2006","unstructured":"Al-Hanbali O, Rutt KJ, Sarker DK, Hunter AC, Moghimi SM (2006) Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. J Nanosci Nanotechnol 6(9\u201310):3126\u20133133","journal-title":"J Nanosci Nanotechnol"},{"issue":"6","key":"13_CR17","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s11095-006-0069-0","volume":"23","author":"I Bertholon","year":"2006","unstructured":"Bertholon I, Vauthier C, Labarre D (2006) Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm Res 23(6):1313\u20131323. doi:\n                    10.1007\/s11095-006-0069-0","journal-title":"Pharm Res"},{"issue":"25","key":"13_CR18","doi-asserted-by":"publisher","first-page":"14577","DOI":"10.1073\/pnas.261428398","volume":"98","author":"Y Xu","year":"2001","unstructured":"Xu Y, Ma M, Ippolito GC, Schroeder HW Jr, Carroll MC, Volanakis JE (2001) Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A 98(25):14577\u201314582. doi:\n                    10.1073\/pnas.261428398","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"13_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.nano.2011.06.003","volume":"8","author":"J Szebeni","year":"2012","unstructured":"Szebeni J, Bedocs P, Rozsnyay Z, Weiszhar Z, Urbanics R, Rosivall L, Cohen R, Garbuzenko O, Bathori G, Toth M, Bunger R, Barenholz Y (2012) Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 8(2):176\u2013184. doi:\n                    10.1016\/j.nano.2011.06.003","journal-title":"Nanomedicine"},{"issue":"1\u20132","key":"13_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1081\/LPR-120004790","volume":"12","author":"J Szebeni","year":"2002","unstructured":"Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P, Metselaar JM, Storm G, Chanan-Khan A, Liebes L, Muggia FM, Cohen R, Barenholz Y, Alving CR (2002) Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res 12(1\u20132):165\u2013172. doi:\n                    10.1081\/lpr-120004790","journal-title":"J Liposome Res"},{"issue":"2","key":"13_CR21","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jconrel.2013.05.025","volume":"172","author":"MA Dobrovolskaia","year":"2013","unstructured":"Dobrovolskaia MA, McNeil SE (2013) Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release 172(2):456\u2013466. doi:\n                    10.1016\/j.jconrel.2013.05.025","journal-title":"J Control Release"},{"key":"13_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-60327-198-1_25","volume":"697","author":"BW Neun","year":"2011","unstructured":"Neun BW, Dobrovolskaia MA (2011) Qualitative analysis of total complement activation by nanoparticles. Methods Mol Biol 697:237\u2013245. doi:\n                    10.1007\/978-1-60327-198-1_25","journal-title":"Methods Mol Biol"}],"container-title":["Methods in Molecular Biology","Characterization of Nanoparticles Intended for Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7352-1_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T03:37:45Z","timestamp":1558064265000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7352-1_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"ISBN":["9781493973507","9781493973521"],"references-count":22,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7352-1_13","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]},"assertion":[{"value":"17 October 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}